Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Heleen A. Crommelin"'
Autor:
Birgitta MG Snijders, Gini Mathijssen, Mike JL Peters, Marielle H Emmelot-Vonk, Pim A de Jong, Susan Bakker, Heleen A Crommelin, Ynte M Ruigrok, Eva H Brilstra, Vera PM Schepers, Wilko Spiering, Evelien van Valen, Huiberdina L Koek
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-8 (2024)
Abstract Background Fahr’s disease and syndrome are rare disorders leading to calcification of the small arteries in the basal ganglia of the brain, resulting in a wide range of symptoms comprising cognitive decline, movement disorders and neuropsy
Externí odkaz:
https://doaj.org/article/0cde0a52159e438b829397bf0e374401
Autor:
Birgitta MG Snijders, Gini Mathijssen, Mike JL Peters, Marielle H Emmelot-Vonk, Pim A de Jong, Susan Bakker, Heleen A Crommelin, Ynte M Ruigrok, Eva H Brilstra, Vera PM Schepers, Wilko Spiering, Evelien van Valen, Huiberdina L Koek
Background Fahr’s disease and syndrome are rare disorders leading to calcification of the small arteries in the basal ganglia of the brain, resulting in a wide range of symptoms comprising cognitive decline, movement disorders and neuropsychiatric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed3b1d6e028549be5bdeef2ba980be6b
https://doi.org/10.21203/rs.3.rs-2813808/v1
https://doi.org/10.21203/rs.3.rs-2813808/v1
Autor:
Coline H.M. van Moorsel, Adriane D.M. Vorselaars, Joanne J. van der Vis, Vera H.M. Deneer, Heleen A. Crommelin
Publikováno v:
Current Opinion in Pulmonary Medicine. 26:267-276
PURPOSE OF REVIEW Antitumor necrosis factor (TNF) treatment is an effective third-line treatment option in severe sarcoidosis. But not all patients respond to treatment. Pharmacogenetics studies the influence of genetic variations on treatment respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8d5e129f40f8276b75e2cffa7db3dc
https://doi.org/10.1097/mcp.0000000000000681
https://doi.org/10.1097/mcp.0000000000000681
Autor:
Frouke T. van Beek, Marcel Veltkamp, Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Ruth G.M. Keijsers, Heleen A. Crommelin, Vera H.M. Deneer
Publikováno v:
Respiratory Medicine. 138:S7-S13
Background Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b7dd966ccd16e45f2e107695c538102
https://doi.org/10.1016/j.rmed.2018.02.009
https://doi.org/10.1016/j.rmed.2018.02.009
Autor:
Milou C, Schimmelpennink, Adriane D M, Vorselaars, Frouke T, van Beek, Heleen A, Crommelin, Vera H M, Deneer, Ruth G M, Keijsers, Marcel, Veltkamp
Publikováno v:
Respiratory medicine.
Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, RemicadeIn this retrospective cohort study, 29 patients treated with the infli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::70f04e72e6ea9994119bd1ec5e21c0d9
https://pubmed.ncbi.nlm.nih.gov/29496351
https://pubmed.ncbi.nlm.nih.gov/29496351
Autor:
Adriane D.M. Vorselaars, Ruth G.M. Keijsers, Marcel Veltkamp, Heleen C. Crommelin, Milou C. Schimmelpennink, Frouke T. van Beek
Publikováno v:
Diffuse Parenchymal Lung Disease.
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy for severe sarcoidosis patients. The originator product of Infliximab, Remicade®, is expensive, which limits universal access.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b53fbc57c9514c1cdfe7854b5ded7fb
https://doi.org/10.1183/1393003.congress-2017.pa3259
https://doi.org/10.1183/1393003.congress-2017.pa3259
Autor:
Ingrid H.E. Korenromp, Coline H.M. van Moorsel, Jan C. Grutters, Vera H.M. Deneer, Adriane D.M. Vorselaars, Heleen A. Crommelin
Publikováno v:
Immunotherapy. 6:1127-1143
Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd8632e9185e1f8fb25580d0393572ac
https://doi.org/10.2217/imt.14.65
https://doi.org/10.2217/imt.14.65
Autor:
Tania Mudrikova, Marcel P. H. van den Broek, Erik M. van Maarseveen, Heleen A. Crommelin, Arjan D. van Zuilen
Publikováno v:
Transplantation Journal. 95:397-402
Background Ritonavir is an extremely strong inhibitor of P450 cytochrome 3A, which is the main metabolizing enzyme of tacrolimus. Subsequently, the pharmacokinetics of tacrolimus are affected to a large extend by the coadministration of ritonavir in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307eba3d00ac5f397efee1b91c95c5f6
https://doi.org/10.1097/tp.0b013e3182734651
https://doi.org/10.1097/tp.0b013e3182734651
Autor:
Jan C. Grutters, Anouk Verwoerd, Anke M.E. Claessen, C H M van Moorsel, A D M Vorselaars, Daniëlle Hijdra, Heleen A. Crommelin
Publikováno v:
Clinical and Experimental Immunology, 185(2), 263. Wiley-Blackwell
Summary Sarcoidosis is a systemic granulomatous disease of unknown aetiology that most commonly affects the lungs. Although elevated levels of regulatory T cells (Tregs) have been reported, the extent to which they play a role in sarcoidosis pathogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662daf580d0920b428107095da512511
https://dspace.library.uu.nl/handle/1874/345369
https://dspace.library.uu.nl/handle/1874/345369
Autor:
Coline H.M. van Moorsel, Heleen A. Crommelin, Ger T. Rijkers, Bob Meek, Jan C. Grutters, Anke M.E. Claessen, Daniëlle Hijdra, Adriane D.M. Vorselaars
Publikováno v:
The European respiratory journal. 48(4)
Responders to infliximab therapy have more intermediate monocytes at baseline compared with non-responders http://ow.ly/fMLp300oVrO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bb92f81e185a464a86755a8b6fb8b6
https://pubmed.ncbi.nlm.nih.gov/27390275
https://pubmed.ncbi.nlm.nih.gov/27390275